I’ve often wondered why Starpharma (with the $49m they raised from shareholders last year) were not also pursuing an early infection COVID-19 treatment trial in humans. As the following snippet from the 25th Aug 2020 update alluded to:
“When SPL7013 was added to cells before or at various stages of the virus replication lifecycle after infection with SARS-CoV-2, no infectious virus was detected, regardless of the initial time of addition of SPL7013 (see Figure 2 below)“
Thoughts?
Updated VIRALEZE™ information, page-74
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
